These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25954630)

  • 21. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
    Staskin DR; Rosenberg MT; Sand PK; Zinner NR; Dmochowski RR
    Int J Clin Pract; 2009 Dec; 63(12):1715-23. PubMed ID: 19930332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yearly Trends of Overactive Bladder Medication Usage.
    Chua KJ; Patel HV; Tabakin A; Srivastava A; Doppalapudi SK; Hyams E; Tunuguntla HSGR
    Urol Pract; 2021 Sep; 8(5):546-554. PubMed ID: 37145398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Trospium chloride once daily for overactive bladder syndrome: results of a multicenter observational study].
    Notz HJ; Hautumm B; Werdier D; Groves R; Odenthal KP
    Urologe A; 2013 Jan; 52(1):65-70. PubMed ID: 23052979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.
    Sand PK; Dmochowski RR; Zinner NR; Staskin DR; Appell RA
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Dec; 20(12):1431-8. PubMed ID: 19727537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Impact of the SARS-CV-2 virus on the urinary bladder].
    Kulchavenya EV; Shevchenko SY
    Urologiia; 2023 Mar; (1):41-45. PubMed ID: 37401682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
    Hill S; Elhilali M; Millard RJ; Dwyer PL; Lheritier K; Kawakami FT; Steel M
    Curr Med Res Opin; 2007 Nov; 23(11):2697-704. PubMed ID: 17892634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.
    Sand PK; Johnson Ii TM; Rovner ES; Ellsworth PI; Oefelein MG; Staskin DR
    BJU Int; 2011 Feb; 107(4):612-20. PubMed ID: 20707790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Charasteristics of the treatment of urinary disorders in postmenopausal women].
    Kulchavenya EV; Treyvish LS; Baranchukova AA
    Urologiia; 2021 Dec; (6):72-77. PubMed ID: 34967168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant medications and possible side effects of antimuscarinic agents.
    Macdiarmid SA
    Rev Urol; 2008; 10(2):92-8. PubMed ID: 18660862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH).
    Oh SJ; Cho ST; Kuo HC; Chou EC; Hsu YC; Lee KS; Hadi F; Song Y; Sumarsono B
    Adv Ther; 2024 Apr; 41(4):1652-1671. PubMed ID: 38430402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
    Staskin D; Sand P; Zinner N; Dmochowski R;
    J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.
    Geller EJ; Crane AK; Wells EC; Robinson BL; Jannelli ML; Khandelwal CM; Connolly A; Parnell BA; Matthews CA; Dumond JB; Busby-Whitehead J
    Clin Drug Investig; 2012 Oct; 32(10):697-705. PubMed ID: 22873491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
    Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
    Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
    Ginsberg DA; Oefelein MG; Ellsworth PI
    Neurourol Urodyn; 2011 Apr; 30(4):563-7. PubMed ID: 21268101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S; Khullar V; Wyndaele JJ; Lheritier K;
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effects of trospium and solifenacin on intraocular pressure and tear secretion in patients with overactive bladder.
    Turkoglu AR; Parmak Yener N; Guzelsoy M; Coban S; Demirci H
    Int Urogynecol J; 2021 Jan; 32(1):173-178. PubMed ID: 32749655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of β3 Agonists and Anticholinergic Drugs on Defecation in Patients With Overactive Bladder.
    Ito H; Matsuo T; Kurata H; Masato M; Mitsunari K; Ohba K; Miyata Y
    In Vivo; 2022; 36(4):1847-1853. PubMed ID: 35738641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.